医学
临床实习
临床试验
重症监护医学
降低胆固醇
低密度脂蛋白胆固醇
风险分析(工程)
药理学
胆固醇
内科学
家庭医学
作者
Salvatore Giordano,Alberto Polimeni,Giovanni Esposito,Ciro Indolfi,Carmen Spaccarotella
标识
DOI:10.1097/mol.0000000000000877
摘要
Purpose of review To highlight critical aspects of inclisiran, from preclinical studies to current recommendations in clinical practice and future perspectives. Recent findings Inclisiran use has been recently approved by regulatory agencies. The evidence of its efficacy and safety makes it a promising therapeutical tool for treating dyslipidemias. Summary The link between LDL-cholesterol and atherosclerotic cardiovascular disease (ASCVD) is well established. Inclisiran, a small interfering RNA, has proven its safety and efficacy in reducing LDL-cholesterol, and FDA and EMA have recently approved its use. This review illustrates the development, structure, and mechanism of action of inclisiran and provides information regarding its efficacy, safety, and current recommendation in clinical practice. Moreover, it provides key information on the most recent/ongoing trials that will help us to implement the use of inclisiran in clinical practice.
科研通智能强力驱动
Strongly Powered by AbleSci AI